Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual meeting format.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005276/en/
Deciphera Pharmaceuticals Stock
Deciphera Pharmaceuticals is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 24 € there is a slightly positive potential of 3.45% for Deciphera Pharmaceuticals compared to the current price of 23.2 €.
